A needle-free route, chosen by clinical determination.
A clinician-selected compounded semaglutide ODT for patients whose individual medical needs support a dissolving oral route.
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
About 10 minutes. No charge unless your clinician approves.
The route is part of the prescription.
Semaglutide is a GLP-1 receptor agonist. The molecule acts on pathways involved in appetite signaling, gastric emptying, and glucose-dependent insulin response. What changes here is not the target. It is how the medication reaches you.
This compounded ODT is designed to dissolve in the mouth rather than arrive by injection. That distinction can matter when injection intolerance, handling constraints, or a documented adherence problem makes the standard route a poor fit. It is not a cosmetic format swap. Your clinician decides whether the alternate route has a real clinical rationale for your case.
The evidence also has to stay attached to the formulation that produced it. Randomized trials of FDA-approved semaglutide finished drug products do not establish equivalent exposure, safety, or effectiveness for this compounded ODT. That does not make the format uninteresting. It makes clinician oversight more important.
Needle-free is only the first consideration. Dissolving delivery, route-matched evidence, and the differences from an injection all matter, while formulation selection remains with the prescriber.
Read the evidence →For when the route is the obstacle.
The Injection-Intolerant
Needle phobia, injection-site problems, or a physical limitation can make self-injection a genuine barrier. You want the route evaluated as part of the medical decision.
The Handling-Constrained
Storage, sharps, or other practical constraints can make an injectable plan harder to execute reliably. Your clinician weighs whether an alternate formulation makes more sense.
The Adherence Case
Your history matters more than a preference survey. If a daily oral routine has held where weekly injections have not, that is useful information for the prescribing conversation.
Compounded semaglutide is not an FDA-approved drug product. This formulation is prescribed where a provider determines the injectable route is unsuitable for you. It is not selectable at checkout.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Semaglutide ODT, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Clinician review of why an alternate route may be appropriate
- Compounded orally disintegrating semaglutide prepared to the individual prescription
- Route-specific prescribing and adjustment rather than injection-dose substitution
- Follow-up tied to response, tolerability, and the broader metabolic plan
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
What the research shows
GLP-1 is a gut hormone released after meals and inactivated extremely rapidly.
The detail
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon, released in response to meal intake, and inactivated extremely rapidly by the enzyme dipeptidyl peptidase-4.1
GLP-1 triggers glucose-dependent insulin release, slows gastric emptying and promotes satiety.
The detail
As an incretin it is secreted within minutes of nutrient ingestion, and incretin-receptor activation on pancreatic islet beta-cells leads to glucose-dependent insulin secretion, while glucagon-like peptide-1 additionally exerts glucoregulatory action through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion and promotes satiety.2
Semaglutide binds the same receptor as the natural hormone it closely resembles.
The detail
Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, the target for the native hormone, and FDA labeling describes the resulting glucose-lowering mechanism as stimulation of insulin secretion and lowering of glucagon secretion, both in a glucose-dependent manner, together with a minor delay in gastric emptying in the early postprandial phase.3
Labeling describes GLP-1 as an appetite regulator, with animal data showing brain activity.
The detail
FDA labeling further describes glucagon-like peptide-1 as a physiological regulator of appetite and caloric intake, states that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and reports that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.4
Albumin binding gives semaglutide a half-life of about one week, so dosing is weekly.
The detail
The pharmacokinetic basis for once-weekly subcutaneous administration is described in the same labeling as albumin binding, identified as the principal mechanism of protraction because it decreases renal clearance and protects against metabolic degradation, with semaglutide extensively bound to plasma albumin at greater than 99 percent, an elimination half-life of approximately one week, and steady-state exposure reached after four to five weekly doses.5
What it does not show
FDA does not verify the safety, effectiveness or quality of compounded drugs.
The detail
A compounded preparation is not an FDA-approved drug product: FDA states that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.7
Everything above is mechanism from labeling, not trial results.
The detail
A pathway is not an outcome. Everything above is drawn from the clinical pharmacology section of FDA labeling, which describes how the molecule acts. This block deliberately stops there rather than reproducing the separate clinical studies section in which trial results for FDA-approved finished drug products are reported, because a described pathway is not a measured outcome.3
No orally disintegrating semaglutide formulation is characterized in FDA labeling.
The detail
FDA labeling characterizes orally administered semaglutide only in tablet formulations co-formulated with the absorption enhancer SNAC, with absorption occurring predominantly in the stomach and absolute oral bioavailability of approximately 0.4 to 2 percent, and no orally disintegrating or oromucosal semaglutide formulation is characterized in FDA labeling.6
Exposure, onset and duration have not been characterized for this compounded preparation.
FDA says compounding is for patients an approved drug cannot serve.
The detail
FDA advises that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and identifies a claim that a compounded drug is the same as an FDA-approved drug as a warning sign for consumers.8
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA-approved semaglutide prescribing information, section 12.1…DailyMed
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- FDA-approved oral semaglutide tablet prescribing information, section…DailyMed
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.FDA
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents, which is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, and significant gastrointestinal disease are screened before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Acute kidney injury following the fluid loss that severe vomiting or diarrhea can cause
Commonly reported
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
The effects patients report most often are gastrointestinal, usually while a dose is being established. Those serious risks are described for FDA-approved finished drug products. This compounded orally disintegrating preparation has no safety database of its own, which is one more reason your clinician weighs the whole picture against your history before deciding whether the alternate route belongs in your plan.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Absorption from an orally disintegrating tablet differs materially from subcutaneous injection, so this is not interchangeable with an injectable product and is not dosed like one. Your provider doses it for its own route and monitors your actual response.
Provider review, your prescription if approved, compounding and fulfillment by the pharmacy, shipping, monthly check-ins, and messaging access to your care team. No separate visit fees. If your plan changes, your provider discusses it with you before your billing does.
The gastrointestinal effects typical of GLP-1 therapy: nausea, constipation, and reflux, most noticeable while your dose is being adjusted. Some patients notice mild taste changes with oral dissolving use. Your provider manages side effects actively and can adjust dose, timing, or format if your comfort requires it.